Biotech Startups

Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies. The company serves cancer patients and their caregivers globally.

11 investors

Cofactor Genomics develops predictive diagnostics for cancer immunotherapy using RNA-expression models to characterize tumor microenvironments and predict patient response. The company serves oncology and precision medicine markets by enabling more accurate patient-to-therapy matching.

11 investors

Debut applies AI and biotechnology to discover and formulate cosmetic ingredients and beauty products, decoding skin and hair at the genomic level to create novel actives. It develops clinically validated ingredients and brand-ready formulations for the beauty industry.

11 investors

Dimension Bio is a biotechnology company developing regenerative therapeutics using its BioNidum platform, which combines materials science, 3D printing, and digital manufacturing to produce implantable and injectable biosynthetic scaffolds that promote tissue healing. Its products target clinical markets such as sports medicine, orthopedics, plastic and reconstructive surgery, aesthetics, dental, and neuro/spine, as well as cell delivery applications for conditions like liver failure and Type 1 diabetes.

11 investors

Biopharma developing HDL-C regulating therapies; listed 2000.

11 investors

Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans. The biotech company focuses on discovering novel therapeutics for human diseases based on evolutionary and genomic insights.

11 investors

Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors. It serves the pharmaceutical industry through both its own drug pipeline and partnerships.

11 investors

ImpriMedicine provides live-cell-based predictive analytics to identify effective drugs for treating blood cancers in dogs and cats, offering patient-specific drug response predictions. The company serves veterinary oncology and drug development efforts in the animal health field.

11 investors

Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.

11 investors

Kanvas Bio operates a platform for discovering, developing, and manufacturing live biotherapeutics based on the human gut microbiome. It combines high-resolution host-microbiome mapping with large-scale anaerobic co-culture manufacturing to support drug development for pharmaceutical and biotechnology partners.

11 investors

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.

11 investors

Leiters Health is an FDA-registered 503B outsourcing facility that produces sterile compounded preparations for hospitals, surgery centers, and ophthalmic use. Founded in 1926, it serves healthcare providers with compounded medications and offers an online ordering portal for registered customers.

11 investors

Modern Meadow develops animal-free, bio-fabricated leather alternatives using synthetic biology and material science for the fashion, interiors, and automotive industries. Its flagship product, INNOVERA™, is engineered from plant-based proteins, biopolymers, and recycled materials to replicate leather performance while maintaining high renewable carbon content.

11 investors

Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.

11 investors

Mytos develops automated manufacturing technology for regenerative medicines, specifically targeting the production of stem cell-derived therapies to make treatments for conditions like Parkinson's, blindness, and spinal cord injury accessible and affordable to patients.

11 investors

Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.

11 investors

One.bio develops food products designed to provide beneficial molecular signals to support health and address chronic inflammatory disease. The company applies rigorous molecular science to food composition and production.

11 investors

Ossium Health develops cellular therapies and bioengineered products for clinical use, leveraging adult stem cell technologies and advanced cell processing platforms. The company operates as a clinical-stage biotech firm manufacturing and distributing cellular therapeutics for patients with organ and tissue diseases.

11 investors

Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.

11 investors

Planet A Foods develops alternative food ingredients using food technology to reduce climate impact in the food industry. The company produces ChoViva, a no-cocoa chocolate ingredient for B2B food manufacturers seeking sustainable supply chain solutions.

11 investors

SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs. The company applies this "neuroimmune modulation" approach to autoimmune disease care.

11 investors

Sonavex develops medical device technologies focused on vascular access and related clinical applications, drawing on ultrasound-based imaging and monitoring products. The company serves clinical and surgical care settings, particularly in the dialysis and renal care space.

11 investors

Strella makes sensors that monitor ethylene, the gas that drives ripening in fruits and vegetables, to track produce freshness across the supply chain. Its technology is used to help manage produce such as apples in the U.S. food supply.

11 investors

TetraScience provides a Scientific Data and AI Platform that produces AI-native scientific data and lab data management products for scientific research and discovery. The platform serves life sciences organizations seeking to accelerate scientific outcomes through collaborative data infrastructure and AI applications.

11 investors